A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED October 01, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide… Read More »
Plasmid CMO VGXI will be speaking at the 22nd Annual ASGCT Meeting in Washington DC. April 04, 2019, The Woodlands, TX – VGXI, Inc., an industry leading plasmid DNA contract manufacturing organization today announced that Mr. Stephen Rodriguez, Sr. Manager, Process Development, will be presenting during the Tools and Technologies Forum of… Read More »
The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting provides an international forum where the latest gene and cell therapy developments are presented and critically discussed. Visit VGXI’s Booth #411 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene or… Read More »
Texas based CMO VGXI Announces Completion of Initial Tech Transfer Milestones as part of its Partnership Agreement for Production of RNA Therapeutics with HMRI. March 15, 2019, The Woodlands, TX – Under a license agreement with the Houston Methodist Research Institute (HMRI) for development of clinical grade RNA manufacturing services, VGXI announced… Read More »
The World Vaccine Congress is a critical strategic partnering event for the global vaccine industry. Visit our Booth #413 or meet with a representative from VGXI during the conference in April to learn more about how our plasmid manufacturing services can support your vaccine program! We welcome meeting requests through the WVC partnering… Read More »
Gene Therapy for Rare Disorders focuses exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. Meet with a representative from VGXI during the conference to learn more about how our plasmid manufacturing services can support your gene therapy products! Contact Us today to schedule a meeting time…. Read More »
Combined with the World Stem Cell Summit, Phacilitate Leaders World is the worlds largest advanced therapies partnering event. Stop by VGXI’s Booth # 713 to meet with representatives from our company and learn more about our plasmid manufacturing products and services! We welcome meeting requests through the Phacilitate partnering website, or contact Us today to schedule… Read More »
U.S. Congressman Kevin Brady visited Texas-based CMO VGXI to celebrate the grand opening of the company’s new flexible scale GMP production plant for DNA and RNA based therapeutics. VGXI, an industry recognized plasmid DNA contract manufacturing organization, announced the grand opening of a facility expansion which includes flexible scale plasmid DNA manufacturing… Read More »
Meet with representatives from VGXI at the 2nd Annual AAV Gene Therapy Symposium on 10 December, 2018. We would welcome an opportunity to introduce ourselves and share information on VGXI’s customized plasmid DNA manufacturing solutions to support your AAV production needs. Contact Us today to request a meeting. 2018 AAV Gene Therapy Symposium 10… Read More »
Will you be attending the Annual Congress of the International Society for Vaccines (ISV) in October, 2018? Meet with representatives from VGXI at Booth # 4 and learn more about our products and services! Or contact Us today to request a meeting time. ISV 2018 Congress 28-30 October, 2018 Marriot Marquis Hotel Atlanta,… Read More »
Will you be attending the 26th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) in October, 2018? Representatives from VGXI will be attending and we would welcome an opportunity to share more about our plasmid DNA products and services! Contact Us today to make arrangements. ESGCT 26th Annual Congress 16-19 October,… Read More »
Texas based CMO VGXI Announces Licensing Agreement with the Houston Methodist Research Institute for Production of RNA Therapeutics. The Woodlands, TX – September 17, 2018: VGXI, an industry leading plasmid DNA contract manufacturer, announced today that they have entered into an exclusive license with the Houston Methodist Research Institute to produce clinical… Read More »
GeneOne Announces that its Subsidiary, Industry Leading Plasmid DNA CMO VGXI, has Entered into an Exclusive License to Produce RNA Biotherapeutics. Seoul, Korea – September 17, 2018: GeneOne Life Science announced today that its subsidiary VGXI, an industry leading plasmid DNA contract manufacturer, has entered into an exclusive license with the Houston… Read More »